Search Results
Nov 12, 2025, 07:00 ET Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury strategy to accumulate Zcash's
More news about: Leap Therapeutics, Inc.
Nov 12, 2025, 07:00 ET Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury
More news about: Leap Therapeutics, Inc.
Oct 20, 2025, 07:00 ET Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
these CRC patients with poor prognosis." About Leap TherapeuticsLeap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's pipeline includes sirexatamab (DKN-01), a humanized monoclonal antibody targeting
More news about: Leap Therapeutics, Inc.
Oct 09, 2025, 07:00 ET Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
rules). About Leap Therapeutics Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's pipeline includes sirexatamab (DKN-01), a humanized monoclonal antibody targeting
More news about: Leap Therapeutics, Inc.
Oct 07, 2025, 09:00 ET Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
capital deployment, clinical-stage immunotherapy developers including GT Biopharma, Inc. (NASDAQ: GTBP), Leap Therapeutics, Inc. (NASDAQ: LPTX), IO Biotech (NASDAQ: IOBT), Celcuity Inc. (NASDAQ: CELC), and MAIA Biotechnology, Inc. (NYSE-American: MAIA).
More news about: USA News Group
Oct 06, 2025, 09:00 ET Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
rules). About Leap Therapeutics Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's pipeline includes sirexatamab (DKN-01), a humanized monoclonal antibody targeting
More news about: Leap Therapeutics, Inc.
Sep 25, 2025, 07:00 ET Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025
Mass., Sept. 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present the final clinical results
More news about: Leap Therapeutics, Inc.